一个与铁死亡相关的基因特征，用于预测肾癌的生存和免疫治疗效果。
A Ferroptosis-Related Gene Signature for Predicting Survival and Immunotherapy Effect in Renal Cancer.
机构信息
Department of Urology, Loudi Central Hospital of Hunan Province, Loudi, China.
出版信息
Comput Math Methods Med. 2022 Aug 17;2022:3317624. doi: 10.1155/2022/3317624. eCollection 2022.
BACKGROUND
Most recently, no efficient prognostic indictor is present for kidney cancer. Thus, we aimed to build and validate a new prognostic gene signature for renal cancer patients using the Cancer Genomic Atlas (TCGA).
METHODS
A "time-dependent receiver operating characteristic (tROC)" curve was generated, and a log-rank test was performed to assess the performance of the biomarker in training and validation. A "ferroptosis-related gene signature" was developed. In different training and validations sets, tROC and log-rank test were used to validate the biomarker's performance.
RESULTS
In the training set with a value less than 0.01 and the validation set, the "gene signature" was significantly correlated with survival. Eventually, it was found that the ferroptosis-related gene signature was directly correlated with immune score and the score of tumor mutation, suggesting its role in predicting response to immunotherapy.
CONCLUSION
We developed and validated a "ferroptosis-related gene signature" that can be sued for patients with kidney cancer. It can also assist in facilitating the plan for treatment and risk stratification.
背景
目前，针对肾癌尚无有效的预后指标。因此，我们旨在利用癌症基因组图谱（TCGA）为肾癌患者构建和验证新的预后基因特征。
方法
生成“时间依赖的接收者操作特征（tROC）”曲线，并进行对数秩检验以评估生物标志物在训练和验证中的性能。开发“铁死亡相关基因特征”。在不同的训练和验证组中，使用 tROC 和对数秩检验来验证生物标志物的性能。
结果
在 值小于 0.01 的训练集和验证集中，“基因特征”与生存显著相关。最终发现，铁死亡相关基因特征与免疫评分和肿瘤突变评分直接相关，表明其在预测免疫治疗反应中的作用。
结论
我们开发并验证了一种“铁死亡相关基因特征”，可用于肾癌患者。它还可以帮助制定治疗和风险分层计划。
Zotero 插件